| 6868 |
Newer Anti-TB Drugs: Pretomanid [Pa] |
03/11/2024 |
|
| 6869 |
WHO recommendation for newer, shorter, oral regimens |
03/11/2024 |
|
| 691 |
Determinants of TB Disease |
03/11/2024 |
Surveillance, SM&E and Epidemiology |
| 630 |
DR-TB Treatment Regimens |
03/11/2024 |
DR-TB and PMDT |
| 6873 |
Evidence for the efficacy of BPaL regimen in DR-TB |
03/11/2024 |
|
| 6874 |
Rationale for continuation of Moxifloxacin in BPaLM regimen irrespective of FQ resistance |
03/11/2024 |
|
| 6875 |
Eligibility Criteria for BPaLM |
03/11/2024 |
|
| 6876 |
Relative contraindications Criteria for BPaLM |
03/11/2024 |
|
| 6877 |
Overview of Treatment Course for patients on BPaLM regimen |
03/11/2024 |
|
| 6878 |
Management of BPaLM ineligible patients |
03/11/2024 |
|
| 6879 |
Regimen modification for patients on BPaLM regimen |
03/11/2024 |
|
| 6880 |
Implementation Consideration for BPaLM regimen |
03/11/2024 |
|
| 6881 |
Extension criterion for BPaLM regimen |
03/11/2024 |
|
| 6882 |
Follow-up monitoring of BPaLM |
03/11/2024 |
|
| 6883 |
Screening of patients on BPaLM regimen for Linezolid toxicity |
03/11/2024 |
|
| 6872 |
BPaLM regimen for DR-TB |
03/11/2024 |
DR-TB and PMDT |
| 6884 |
Switching from BPaLM to another regimen |
03/11/2024 |
DR-TB and PMDT |
| 6885 |
Principles of Switching to BPal from Shorter Oral Regimen |
03/11/2024 |
|
| 6886 |
Principles of Switching from BpalL/ Shorter Oral Regimen to Longer Oral Regimen |
03/11/2024 |
|
| 6887 |
Refreshing BDQ course after switching between regimens |
03/11/2024 |
|
| 1815 |
Management of Hepato-toxicity During treatment with MDR/RR-TB Regimen |
03/11/2024 |
DR-TB and PMDT |
| 6888 |
Management of DR-TB Treatment interruptions |
03/11/2024 |
|
| 6889 |
Long term follow-up for DR-TB treatment |
03/11/2024 |
|
| 6890 |
Ambulatory care for DR-TB patients |
03/11/2024 |
|
| 6891 |
Peripheral neuropathy screening tool |
03/11/2024 |
|
| 6892 |
DAIDS scale for assessment of Peripheral Neuropathy |
03/11/2024 |
|
| 64 |
Genotypic Tests |
03/11/2024 |
Laboratory services and management |
| 6893 |
Discordance resolution in RR between LPA and NAAT |
03/11/2024 |
|
| 6894 |
Follow-up monitoring of modified shorter oral MDR/RR-TB regimen with Lzd |
03/11/2024 |
|
| 1094 |
Shorter oral Bedaquiline-containing MDR/RR-TB regimen |
03/11/2024 |
DR-TB and PMDT |
